(WRK)4

• CAT Number: I038332
• Molecular Formula: C92H139N33O12
• Molecular Weight: 1899.34
• Purity: 98%
• Synonyms: (WRK)4; (WRK) 4; (WRK)-4
• Solubility: To be determined
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: (S)-2-((6S,9S,12S,15S)-12-((1H-indol-3-yl)methyl)-1-amino-6-((S)-2-amino-3-(1H-indol-3-yl)propanamido)-9-(4-aminobutyl)-15-(3-guanidinopropyl)-1-imino-7,10,13-trioxo-2,8,11,14-tetraazahexadecan-16-amido)-N-((2S,5S,8S,11S,14S,17S)-11-((1H-indol-3-yl)methyl)-21-amino-8-(4-aminobutyl)-17-carbamoyl-5,14-bis(3-guanidinopropyl)-1-(1H-indol-3-yl)-3,6,9,12,15-pentaoxo-4,7,10,13,16-pentaazahenicosan-2-yl)-6-aminohexanamide
• InChI: InChI=1S/C92H139N33O12/c93-37-13-9-29-66(77(98)126)115-79(128)71(34-18-42-108-90(101)102)120-86(135)74(46-54-50-112-63-26-6-2-22-58(54)63)123-84(133)68(31-11-15-39-95)118-81(130)73(36-20-44-110-92(105)106)122-88(137)76(48-56-52-114-65-28-8-4-24-60(56)65)125-85(134)69(32-12-16-40-96)119-82(131)72(35-19-43-109-91(103)104)121-87(136)75(47-55-51-113-64-27-7-3-23-59(55)64)124-83(132)67(30-10-14-38-94)117-80(129)70(33-17-41-107-89(99)100)116-78(127)61(97)45-53-49-111-62-25-5-1-21-57(53)62/h1-8,21-28,49-52,61,66-76,111-114H,9-20,29-48,93-97H2,(H2,98,126)(H,115,128)(H,116,127)(H,117,129)(H,118,130)(H,119,131)(H,120,135)(H,121,136)(H,122,137)(H,123,133)(H,124,132)(H,125,134)(H4,99,100,107)(H4,101,102,108)(H4,103,104,109)(H4,105,106,110)/t61-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-/m0/s1
• InChIKey: FZNHAQVJFVYBNX-XRMNIVIASA-N
• SMILES: O=C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CC3=CNC4=CC=CC=C34)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CC5=CNC6=CC=CC=C56)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC7=CNC8=CC=CC=C78)N

(WRK)4(CAT: I038332) is a novel antimicrobial peptide featuring a repeating unit structure designed to combat multidrug-resistant (MDR) bacteria effectively. Its innovative composition disrupts bacterial membranes, making it a powerful tool in antimicrobial resistance research. (WRK)4 exhibits broad-spectrum activity against MDR pathogens, including Gram-positive and Gram-negative bacteria, and holds potential for addressing critical healthcare challenges. With its high stability and efficacy, this peptide is ideal for preclinical studies exploring alternative antimicrobial strategies, advancing drug discovery efforts, and developing novel therapies for resistant bacterial infections.